Evaluation of endoscopic mucosal resection and nodal micrometastasis in pN0 submucosal gastric cancer

Kazuya Endo, Shunji Kohnoe, Takeshi Okamura, Masaru Haraguchi, Kenichi Nishiyama, Yasushi Toh, Hideo Baba, Yoshihiko Maehara

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Endoscopic mucosal resection (EMR) is a minimally invasive, standard treatment for intramucosal (early) gastric cancers, but is not standard for submucosal gastric cancers based on existing criteria. We evaluated the possibility of extending EMR as a therapy for submucosal gastric cancers by analyzing nodal micrometastasis through immunohistochemical staining in patients with apparent node-negative submucosal gastric cancer, the patients for whom EMR might be appropriate. We used anti-cytokeratin (AE1/AE3) antibody to immunohistochemically detect nodal micrometastasis that was not identified by routine pathological examination in 162 patients (total, 2048 lymph nodes) with apparent node-negative submucosal gastric cancer. The relationship between the incidence of nodal micrometastasis and clinicopathological factors was analyzed. Micrometastasis was detected in 45 of 2048 nodes (2.2%), representing 31 of 162 patients (19%). A significantly high incidence of nodal micrometastasis was found with submucosal cancers of large size (>2 cm), as well as with tumors that showed lymphatic or venous invasion and deeper submucosal invasion (p<0.0001). Nodal micrometastasis was also recognized in 2 cases of histologically well-differentiated tumors with focal submucosal invasion without venous or lymphatic invasion. Of the 162 patients, only 2 died of recurrent disease regardless of nodal involvement. Based on the present results, risk factors for nodal micrometastasis are tumor size, presence of lymphatic-vascular invasion, and depth of tumor, which are nearly the same as those established in previous pathological studies that used hematoxylin and eosin staining. We conclude that EMR is not recommended for patients with submucosal gastric cancer.

Original languageEnglish
Pages (from-to)1059-1063
Number of pages5
JournalOncology reports
Volume13
Issue number6
Publication statusPublished - Jun 1 2005

Fingerprint

Neoplasm Micrometastasis
Stomach Neoplasms
Neoplasms
Staining and Labeling
Incidence
Hematoxylin
Eosine Yellowish-(YS)
Keratins
Endoscopic Mucosal Resection
Blood Vessels
Lymph Nodes
Antibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Endo, K., Kohnoe, S., Okamura, T., Haraguchi, M., Nishiyama, K., Toh, Y., ... Maehara, Y. (2005). Evaluation of endoscopic mucosal resection and nodal micrometastasis in pN0 submucosal gastric cancer. Oncology reports, 13(6), 1059-1063.

Evaluation of endoscopic mucosal resection and nodal micrometastasis in pN0 submucosal gastric cancer. / Endo, Kazuya; Kohnoe, Shunji; Okamura, Takeshi; Haraguchi, Masaru; Nishiyama, Kenichi; Toh, Yasushi; Baba, Hideo; Maehara, Yoshihiko.

In: Oncology reports, Vol. 13, No. 6, 01.06.2005, p. 1059-1063.

Research output: Contribution to journalArticle

Endo, K, Kohnoe, S, Okamura, T, Haraguchi, M, Nishiyama, K, Toh, Y, Baba, H & Maehara, Y 2005, 'Evaluation of endoscopic mucosal resection and nodal micrometastasis in pN0 submucosal gastric cancer', Oncology reports, vol. 13, no. 6, pp. 1059-1063.
Endo K, Kohnoe S, Okamura T, Haraguchi M, Nishiyama K, Toh Y et al. Evaluation of endoscopic mucosal resection and nodal micrometastasis in pN0 submucosal gastric cancer. Oncology reports. 2005 Jun 1;13(6):1059-1063.
Endo, Kazuya ; Kohnoe, Shunji ; Okamura, Takeshi ; Haraguchi, Masaru ; Nishiyama, Kenichi ; Toh, Yasushi ; Baba, Hideo ; Maehara, Yoshihiko. / Evaluation of endoscopic mucosal resection and nodal micrometastasis in pN0 submucosal gastric cancer. In: Oncology reports. 2005 ; Vol. 13, No. 6. pp. 1059-1063.
@article{02ee0b8208cd4307b5330e13a690e9c0,
title = "Evaluation of endoscopic mucosal resection and nodal micrometastasis in pN0 submucosal gastric cancer",
abstract = "Endoscopic mucosal resection (EMR) is a minimally invasive, standard treatment for intramucosal (early) gastric cancers, but is not standard for submucosal gastric cancers based on existing criteria. We evaluated the possibility of extending EMR as a therapy for submucosal gastric cancers by analyzing nodal micrometastasis through immunohistochemical staining in patients with apparent node-negative submucosal gastric cancer, the patients for whom EMR might be appropriate. We used anti-cytokeratin (AE1/AE3) antibody to immunohistochemically detect nodal micrometastasis that was not identified by routine pathological examination in 162 patients (total, 2048 lymph nodes) with apparent node-negative submucosal gastric cancer. The relationship between the incidence of nodal micrometastasis and clinicopathological factors was analyzed. Micrometastasis was detected in 45 of 2048 nodes (2.2{\%}), representing 31 of 162 patients (19{\%}). A significantly high incidence of nodal micrometastasis was found with submucosal cancers of large size (>2 cm), as well as with tumors that showed lymphatic or venous invasion and deeper submucosal invasion (p<0.0001). Nodal micrometastasis was also recognized in 2 cases of histologically well-differentiated tumors with focal submucosal invasion without venous or lymphatic invasion. Of the 162 patients, only 2 died of recurrent disease regardless of nodal involvement. Based on the present results, risk factors for nodal micrometastasis are tumor size, presence of lymphatic-vascular invasion, and depth of tumor, which are nearly the same as those established in previous pathological studies that used hematoxylin and eosin staining. We conclude that EMR is not recommended for patients with submucosal gastric cancer.",
author = "Kazuya Endo and Shunji Kohnoe and Takeshi Okamura and Masaru Haraguchi and Kenichi Nishiyama and Yasushi Toh and Hideo Baba and Yoshihiko Maehara",
year = "2005",
month = "6",
day = "1",
language = "English",
volume = "13",
pages = "1059--1063",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Evaluation of endoscopic mucosal resection and nodal micrometastasis in pN0 submucosal gastric cancer

AU - Endo, Kazuya

AU - Kohnoe, Shunji

AU - Okamura, Takeshi

AU - Haraguchi, Masaru

AU - Nishiyama, Kenichi

AU - Toh, Yasushi

AU - Baba, Hideo

AU - Maehara, Yoshihiko

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Endoscopic mucosal resection (EMR) is a minimally invasive, standard treatment for intramucosal (early) gastric cancers, but is not standard for submucosal gastric cancers based on existing criteria. We evaluated the possibility of extending EMR as a therapy for submucosal gastric cancers by analyzing nodal micrometastasis through immunohistochemical staining in patients with apparent node-negative submucosal gastric cancer, the patients for whom EMR might be appropriate. We used anti-cytokeratin (AE1/AE3) antibody to immunohistochemically detect nodal micrometastasis that was not identified by routine pathological examination in 162 patients (total, 2048 lymph nodes) with apparent node-negative submucosal gastric cancer. The relationship between the incidence of nodal micrometastasis and clinicopathological factors was analyzed. Micrometastasis was detected in 45 of 2048 nodes (2.2%), representing 31 of 162 patients (19%). A significantly high incidence of nodal micrometastasis was found with submucosal cancers of large size (>2 cm), as well as with tumors that showed lymphatic or venous invasion and deeper submucosal invasion (p<0.0001). Nodal micrometastasis was also recognized in 2 cases of histologically well-differentiated tumors with focal submucosal invasion without venous or lymphatic invasion. Of the 162 patients, only 2 died of recurrent disease regardless of nodal involvement. Based on the present results, risk factors for nodal micrometastasis are tumor size, presence of lymphatic-vascular invasion, and depth of tumor, which are nearly the same as those established in previous pathological studies that used hematoxylin and eosin staining. We conclude that EMR is not recommended for patients with submucosal gastric cancer.

AB - Endoscopic mucosal resection (EMR) is a minimally invasive, standard treatment for intramucosal (early) gastric cancers, but is not standard for submucosal gastric cancers based on existing criteria. We evaluated the possibility of extending EMR as a therapy for submucosal gastric cancers by analyzing nodal micrometastasis through immunohistochemical staining in patients with apparent node-negative submucosal gastric cancer, the patients for whom EMR might be appropriate. We used anti-cytokeratin (AE1/AE3) antibody to immunohistochemically detect nodal micrometastasis that was not identified by routine pathological examination in 162 patients (total, 2048 lymph nodes) with apparent node-negative submucosal gastric cancer. The relationship between the incidence of nodal micrometastasis and clinicopathological factors was analyzed. Micrometastasis was detected in 45 of 2048 nodes (2.2%), representing 31 of 162 patients (19%). A significantly high incidence of nodal micrometastasis was found with submucosal cancers of large size (>2 cm), as well as with tumors that showed lymphatic or venous invasion and deeper submucosal invasion (p<0.0001). Nodal micrometastasis was also recognized in 2 cases of histologically well-differentiated tumors with focal submucosal invasion without venous or lymphatic invasion. Of the 162 patients, only 2 died of recurrent disease regardless of nodal involvement. Based on the present results, risk factors for nodal micrometastasis are tumor size, presence of lymphatic-vascular invasion, and depth of tumor, which are nearly the same as those established in previous pathological studies that used hematoxylin and eosin staining. We conclude that EMR is not recommended for patients with submucosal gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=24744462752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24744462752&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1059

EP - 1063

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -